Bicycle Therapeutics (NASDAQ:BCYC) Sets New 12-Month Low – Time to Sell?

Bicycle Therapeutics plc (NASDAQ:BCYC) shares hit a new 52-week low during trading on Monday . The company traded as low as $10.80 and last traded at $10.83, with a volume of 5024 shares trading hands. The stock had previously closed at $10.97.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on BCYC shares. Stephens restated an “equal weight” rating and set a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. B. Riley dropped their price target on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. HC Wainwright reiterated a “buy” rating and issued a $33.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. JMP Securities lowered their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a research note on Wednesday, December 18th. Finally, Needham & Company LLC restated a “buy” rating and issued a $30.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.14.

Bicycle Therapeutics Trading Up 2.4 %

The firm has a market capitalization of $716.70 million, a P/E ratio of -3.16 and a beta of 1.12. The business’s fifty day moving average is $13.02 and its 200 day moving average is $19.10.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.47 million. During the same quarter in the previous year, the business posted ($1.16) earnings per share. The firm’s quarterly revenue was down 30.2% compared to the same quarter last year. As a group, sell-side analysts predict that Bicycle Therapeutics plc will post -3.06 earnings per share for the current fiscal year.

Insider Transactions at Bicycle Therapeutics

In other news, Director Bros. Advisors Lp Baker bought 985,397 shares of the company’s stock in a transaction dated Friday, December 13th. The shares were acquired at an average cost of $13.76 per share, with a total value of $13,559,062.72. Following the completion of the transaction, the director now directly owns 9,537,643 shares in the company, valued at approximately $131,237,967.68. The trade was a 11.52 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Travis Alvin Thompson sold 2,686 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $15.00, for a total transaction of $40,290.00. Following the sale, the chief accounting officer now owns 32,146 shares in the company, valued at $482,190. This represents a 7.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,677 shares of company stock valued at $392,413 over the last three months. Company insiders own 8.50% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Harbor Capital Advisors Inc. lifted its stake in Bicycle Therapeutics by 141.8% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 133,707 shares of the company’s stock worth $3,026,000 after acquiring an additional 78,418 shares in the last quarter. Principal Financial Group Inc. acquired a new position in shares of Bicycle Therapeutics in the 3rd quarter valued at about $10,028,000. Assetmark Inc. purchased a new stake in shares of Bicycle Therapeutics in the third quarter worth approximately $34,000. Crossmark Global Holdings Inc. purchased a new stake in shares of Bicycle Therapeutics in the third quarter worth approximately $257,000. Finally, L & S Advisors Inc boosted its holdings in shares of Bicycle Therapeutics by 2.4% during the third quarter. L & S Advisors Inc now owns 59,735 shares of the company’s stock worth $1,352,000 after purchasing an additional 1,400 shares during the period. Institutional investors and hedge funds own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.